| |
|
| November 10 |
|
 |
Niacin Plus Statins Slows Atherosclerotic Progression November 10, 2004 (eshonline.org) - A 68% reduction in carotid artery atherosclerosis, measured as carotid intimal medial thickening, when adding prescription extended-release niacin to statin therapy in patients with coronary heart disease (CHD) on a statin with an LDL-cholesterol < 130 mg/dL and an HDL-cholesterol < 45 mg/dL. 
|
| |
|
|
CARP: No Improvement from Revascularization Before Elective Vascular Surgery
November 10, 2004 (eshonline.org) - Prophylactic revascularization performed before major elective vascular surgery does not provide short-term benefit or improve long-term survival and can delay or prevent surgery in patients with coronary artery disease.
|
| |
|
|
Single Chamber ICD Cost Effective Treatment in SCD-HeFT Population
November 10, 2004 (eshonline.org) - A single chamber implanted cardio defibrillator (ICD), shown to reduce all-cause mortality in the SCD-HeFT trial, is cost effective, while amiodarone without any mortality benefit in the main trial was no more cost effective than placebo.
|
| |
|
|
Pioglitazone Improves Lipid Profile Beyond Glycemic Control
November 10, 2004 (eshonline.org) - In patients with type II diabetes and dyslipidemia, pioglitazone significantly improved triglycerides, HDL-cholesterol, non-HDL-cholesterol, and LDL particle concentration and size, compared to rosiglitazone in a 24-week comparison in 735 patients (56 years old, 50% male).
|
| |
|
| |
|
| November 9 |
|
|
GEMINI: Carvedilol Safe in Patients with Diabetes and Hypertension
November 9, 2004 (eshonline.org) - Carvedilol had a neutral effect on glycemic control and improved components of the metabolic syndrome, including blood pressure, in the presence of renin-angiotensin system blockade.
|
| |
|
|
ESCAPE: Pulmonary Artery Catheterization in Severe Heart Failure Neutral for Mortality and Hospitalization
November 9, 2004 (eshonline.org) - The Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) Trial in patients with advanced heart failure showed that pulmonary artery catheter (PAC), also known as the Swan-Ganz catheter, did not impact the composite primary endpoint of time to death, death plus hospitalization, or days hospitalized (hazard ratio 1.00).
|
| |
|
|
SEEDS: Designated Syncope Unit Improves Diagnosis, Reduces Hospitalization
November 9, 2004 (eshonline.org) - The single center Syncope Evaluation in the Emergency Department Study (SEEDS) demonstrated that a designated syncope evaluation unit is an effective and efficient method to provide emergent care of the large population of patients who present to the emergency department for a syncopal event to rule out high-risk patients and thus follow non-cardiac syncope on an outpatient basis.
|
| |
|
|
RIO-NA Confirms RIO-Europe and RIO-Lipids Results
November 9, 2004 (eshonline.org) – The Rimonabant in North America (RIO-NA) trial showed that the investigational cannabinoid type 1 receptor reduced body weight and waist circumference and significantly reduced central adiposity.
|
| |
|
|
Lower BP in CAD Heralded by CAMELOT
November 9, 2004 (eshonline.org) - In patients with coronary artery disease (CAD) and a baseline blood pressure of only 129/78 mm Hg, a 31% relative reduction in cardiovascular events (CVE) was produced by a 5/3 mm Hg reduction in blood pressure with amlodipine compared to placebo in the CAMELOT trial.
|
| |
|
| |
|
| November 8 |
|
|
Treatment of Understudied Mechanism Improves Outcomes in Heart Failure
November 8, 2004 (eshonline.org) - A fixed-dose combination of isosorbide dinitrate and hydralazine (IDN/HY), compared to placebo, added to standard background therapy for heart failure, reduced mortality by 43% (p=0.01) and reduced first hospitalizations for heart failure by 33% in the A-HeFT (African American in Heart Failure) trial. A-HeFT was presented today at the 2004 American Heart Association Scientific Sessions and simultaneously published by the New England Journal of Medicine (2004;351:2049-2057).
|
| |
|
|
Azimilide Reduces Ventricular Tachyarrhythmias in Patients with ICD
November 8, 2004 (eshonline.org) - The SHIELD (Shock Inhibition Evaluation with Azimilide) study demonstrated that the investigational drug azimilide significantly reduced the recurrence of ventricular tachycardia (VT) or ventricular fibrillation (VF) terminated by shocks or by antitachycardia pacing (ATP). Azimilide is an Ikr and Iks potassium channel blocker with a class III antiarrhythmic effect. |
| |
|
|
First Demonstration of Mortality Benefit with an Antithrombotic in CREATE Trial November 8, 2004 (eshonline.org) - An investigator-led study of 15,570 patients with ST segment elevation myocardial infarction (MI) or new bundle branch block presenting within 12 hours of symptom onset showed that the low molecular weight reviparin reduced mortality by 13% (p=0.005) and reduced reinfarction by 23% (p=0.014), while there was no difference in stroke between the 2 groups.
|
| |
|
|
No Mortality Reduction with Glucose-Insulin-Potassium Therapy in Patients with STEMI
November 8, 2004 (eshonline.org) - The CREATE-ECLA trial reported today at the American Heart Association Scientific Sessions showed that intravenous glucose-insulin-potassium (GIK) therapy administered within 12 hours of symptom onset had no impact on all-cause mortality, cardiac death, cardiac arrhythmia, or cardiogenic shock.
|
| |
|
| |
|
| November 7 |
|
|
PEACE Trial Yields Unexpected Findings with Additive ACE Inhibitor Therapy
November 7, 2004 (eshonline.org) – Adding the ACE inhibitor trandolapril to optimal conventional therapy in patients with stable coronary heart disease and preserved left ventricular function did not reduce atherosclerotic-related events in the double-blind, placebo-controlled PEACE (Prevention of Events with Angiotensin Converting Enzyme Inhibition) trial. PEACE was presented at the American Heart Association meeting and simultaneously published by the New England Journal of Medicine (NEJM 2004;351:2058-2068).
|
| |
|
|
Novel Device Improves Outcomes and Functional Capacity in Heart Failure Patients
November 7, 2004 (eshonline.org) – The novel investigational CorCap™ Cardiac Support Device (CSD) reversed the natural history of heart failure, as indicated by improvements in the size and shape of the left ventricle, and improvements in the clinical score, fewer major cardiac procedures, and improvements in quality of life, in a study reported at the American Heart Association Scientific Sessions 2004.
|
| |
|
|
Survival Benefit but No Cost Savings Found in Disease Management of Heart Failure
November 7, 2004 (eshonline.org) – A statistically significant reduction in mortality (p=0.037) was found in patients randomized to the intervention group (disease management by telephone) compared to the control group, in this trial presented at the American Heart Association Scientific Sessions 2004.
|
| |
|
| |
|
|
| The materials presented here were prepared by independent authors under the editorial supervision of ESHonline, and do not represent a publication of the American Heart Association. These materials and the related activity are not sanctioned by the American Heart Association and do not constitute an official part of that conference. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © ESHonline.org. |
